

It is our great honor to be the Editors of this book and to write the preface on prostate cancer (PCa). It has been an arduous and exciting four years of collecting and organizing for this book, which is a worthwhile and valuable endeavor.

Prostate cancer is the most common malignancy of the urinary system, and the second leading cause of cancer death in males worldwide. Early or localized PCa patients can be treated effectively via various methods, including active surveillance, watchful waiting, endocrine therapy, surgery, and radiation. However, management for advanced diseases remains a difficult problem. Indeed, we firmly believe that these extant limitations will be overcome, and the problems in PCa will be solved by future advance of science and technology. We have thus taken the opportunity to discuss the latest progress in research and detail its future direction with experts worldwide.


Although laparoscopic surgery and robotic surgery continue to be widely used in the treatment of PCa, there are still various problems in surgical treatment, such as selection of appropriate surgical methods, postoperative sexual function and urinary continence, neoadjuvant therapy and postoperative adjuvant therapy, and others. With these problems in mind, we invited key leaders to discuss the difficulties in surgical and medical treatment. With the development of artificial intelligence, along with precision and individualized treatments, these problems can be approached from a new perspective. Only by constantly exploring can we break through the cognitive limitations and obtain greater knowledge concerning disease: this is why we compiled this book.

This book is divided into six parts: “Debates and difficulty in surgical and medical treatment”, “Exploration and advances in radiotherapy”, “Diagnosis, follow-up and prognosis evaluation”, “Precision medicine for individualized therapy”, “Basic research and translational medicine”, and “Research and perspectives from fresh vision”. The book brings together the views from a wide array of international experts on the pressing issues of diagnosis and treatment in PCa. Given its enlightening value for clinical practice and scientific research, we recommend this book as reading for all urologists and other professionals serving in this field.



Xiao Li, MD, PhD

Department of Urologic Surgery,
Jiangsu Cancer Hospital
& Jiangsu Institute of Cancer Research
& Affiliated Cancer Hospital of Nanjing Medical University,
Nanjing, China



Zhiying Qian, MD

Department of Medical Oncology,
Jiangsu Cancer Hospital
& Jiangsu Institute of Cancer Research
& Affiliated Cancer Hospital of Nanjing Medical University,
Nanjing, China